Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 7
Submit an article Journal homepage
1,291
Views
2
CrossRef citations to date
0
Altmetric
Comment

DAPA-HF applicability: the point of view of a cardiology setting

Massimo Iacovielloa Medical and Surgical Sciences Department, University of Foggia, Foggia, ItalyView further author information
,
Marco Marinib Cardiovascular Sciences Cardiology Department, Ospedali Riuniti, Ancona, ItalyView further author information
,
Mauro Goric Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyView further author information
,
Francesco Orsod Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyView further author information
,
Lucio Gonzinie ANMCO Research Center, Heart Care Foundation, Florence, ItalyView further author information
,
Marco Gorinie ANMCO Research Center, Heart Care Foundation, Florence, ItalyView further author information
,
Peter Fenicif Catholic University of the Sacred Heart, School of Medicine and Surgery, Rome, Italy;g Biomagnetism and Clinical Physiology International Center (BACPIC), Rome, Italy;h Medical Affairs, AstraZeneca S.p.A, Milan, ItalyView further author information
&
Aldo Pietro Maggionie ANMCO Research Center, Heart Care Foundation, Florence, ItalyCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-2764-6779View further author information
ORCID Icon show all
Pages 840-845 | Received 01 Feb 2023, Accepted 27 Jul 2023, Published online: 22 Aug 2023

References

  • Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829. doi:10.1016/S0140-6736(20)31824-9.
  • Barbarawi M, Al-Abdouh A, Barbarawi O, et al. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2022;27(3):951–960. doi:10.1007/s10741-021-10083-z.
  • Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298–309. doi:10.1161/CIRCULATIONAHA.120.050391.
  • McMurray JJV, Solomon SD, Inzucchi SE; DAPA-HF Trial Committees and Investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303.
  • Packer M, Anker SD, Butler J; the EMPEROR-Reduced Trial Investigators., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190.
  • Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020;141(2):90–99. doi:10.1161/CIRCULATIONAHA.119.044138.
  • Anker SD, Butler J, Filippatos G; the EMPEROR-Preserved Trial Investigators., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038.
  • Thorvaldsen T, Ferrannini G, Mellbin L, et al. Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. J Card Fail. 2022;28(7):1050–1062. doi:10.1016/j.cardfail.2022.04.011.
  • Lam CSP, Karasik A, Melzer-Cohen C; CVD-REAL Investigators and Study Group., et al. Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: analysis from the CVD-REAL 2 study. Diabetes Obes Metab. 2021;23(6):1431–1435. doi:10.1111/dom.14356.
  • Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-Art review. JACC Basic Transl Sci. 2020;5(6):632–644. doi:10.1016/j.jacbts.2020.02.004.
  • Joshi SS, Singh T, Newby DE, et al. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107(13):1032–1038. doi:10.1136/heartjnl-2020-318060.
  • Cherney DZI, Repetto E, Wheeler DC, et al. Impact of cardio-renal-metabolic comorbidities on cardiovascular outcomes and mortality in type 2 diabetes mellitus. Am J Nephrol. 2020;51(1):74–82. doi:10.1159/000504558.
  • Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi:10.1002/ejhf.1858.
  • Maggioni AP, Orso F, Calabria S; ARNO Observatory., et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail. 2016;18(4):402–410. doi:10.1002/ejhf.471.
  • Averitt AJ, Weng C, Ryan P, et al. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med. 2020;3:67. doi:10.1038/s41746-020-0277-8.
  • Roberts MH, Ferguson GT. Real-world evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon Open. 2021;5(1):3–11. doi:10.1007/s41669-020-00221-y.
  • Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative. Circulation. 2021;143(10):1002–1013. doi:10.1161/CIRCULATIONAHA.120.051718.
  • Tavazzi L, Senni M, Metra M; IN-HF (Italian Network on Heart Failure) Outcome Investigators., et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013;6(3):473–481. doi:10.1161/CIRCHEARTFAILURE.112.000161.
  • The Heart Failure Policy Network. The Heart Failure Policy Practice in Europe. Italy. Available at: https://www.hfpolicynetwork.org/wp-content/uploads/Heart-failure-policy-and-practice-in-Europe-Italy.pdf. accessed 8 August 2022.
  • Piccinni C, Dondi L, Calabria S, et al. How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. Int J Cardiol. 2023;371:236–243. Epub 2022 Sep 27. doi:10.1016/j.ijcard.2022.09.053.
  • Håkansson E, Norberg H, Själander S, et al. Eligibility of dapagliflozin and empagliflozin in a real-world heart failure population. Cardiovasc Ther. 2021 Dec 26;2021:1894155. doi:10.1155/2021/1894155.
Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.